Date: 2015-12-03
Type of information: Opening of new premises
Compound: Global Innovation Center
Company: Baxalta (USA - IL)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases - Immunological diseases - Cancer- Oncology
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On December 3, 2015, Baxalta announced the official opening of its Global Innovation Center in Cambridge, Massachusetts. The Center is located in Kendall Square at 650 East Kendall Street and will act as the innovation hub of the company’s global infrastructure designed to effectively deliver advanced treatments to patients. Baxalta’s innovation efforts are focused on the development of lifesaving therapies in hematology, immunology and oncology. The company’s approach to expanding its pipeline is based on an external innovation model, sourcing compounds externally through in-licensing or acquisitions. The Cambridge life science community will provide Baxalta access to a range of innovations and collaboration partners with complementary expertise to advance new treatments for patients. The Center supports cross-functional, co-located teams including R&D, Oncology, Biosimilars, Business Development, Corporate Strategy and Customer Operations, along with others that support or work closely with R&D. By the end of 2015, Baxalta expects to employ approximately 500 individuals at the Global Innovation Center. In addition, the company also operates a hemophilia treatment manufacturing facility in Milford, Massachusetts.
Financial terms:
Latest news:
